Invivyd (IVVD) Aperçu de l'action
Invivyd, Inc. et ses filiales se consacrent à la recherche, au développement, à la commercialisation et à la vente de thérapies à base d'anticorps pour la prévention et le traitement des maladies infectieuses virales aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
IVVD Community Fair Values
Create NarrativeSee what 79 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Invivyd, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$1.09 |
| Plus haut sur 52 semaines | US$3.07 |
| Plus bas sur 52 semaines | US$0.48 |
| Bêta | 0.71 |
| Variation sur 1 mois | -35.12% |
| Variation sur 3 mois | -32.30% |
| Variation sur 1 an | 42.58% |
| Variation sur 3 ans | -33.94% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | -94.78% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Apr 26
IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. They are keeping fair value around $10.00 per share while fine tuning the risk and profitability profile that underpins the estimate.Mise à jour du récit • Apr 11
IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to $10.00 from $10.00, reflecting updated views on discount rate, revenue growth expectations, profit margin and future P/E assumptions. What's in the News Invivyd reported progress in the REVOLUTION clinical program for VYD2311, including the pivotal DECLARATION Phase 3 study assessing VYD2311 for pre-exposure COVID-19 prophylaxis versus placebo over 90 days, with a blinded sample size re-estimation that triggered an upsizing of approximately 500 subjects to support statistical power.Recent updates
Mise à jour du récit • Apr 26
IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. They are keeping fair value around $10.00 per share while fine tuning the risk and profitability profile that underpins the estimate.Mise à jour du récit • Apr 11
IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to $10.00 from $10.00, reflecting updated views on discount rate, revenue growth expectations, profit margin and future P/E assumptions. What's in the News Invivyd reported progress in the REVOLUTION clinical program for VYD2311, including the pivotal DECLARATION Phase 3 study assessing VYD2311 for pre-exposure COVID-19 prophylaxis versus placebo over 90 days, with a blinded sample size re-estimation that triggered an upsizing of approximately 500 subjects to support statistical power.Mise à jour du récit • Mar 26
IVVD: Phase 3 COVID Prevention And Long COVID Trial Will Drive Upside
Narrative Update on Invivyd Analysts have modestly adjusted their price view on Invivyd, with the updated fair value holding at $10.00. Small tweaks to discount rate, revenue growth, profit margin assumptions, and a higher future P/E estimate of about 282x refine the underlying model rather than signal a major shift in conviction.Seeking Alpha • Mar 20
Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching
Summary Invivyd, Inc. is advancing VYD2311, a next-gen monoclonal antibody for COVID-19 prevention, with pivotal Phase 3 DECLARATION data expected mid-2026. IVVD's Pemgarda generated $53.4M in 2025 revenue, but fell short of management expectations; net loss narrowed to $(52.5M) from $(170M) prior year. IVVD secured FDA Fast Track for VYD2311 and raised ~$200M in 2H 2025, providing at least two years of funding at current burn rates. I view IVVD stock as a high-risk, high-reward opportunity; DECLARATION study success could drive shares up 75%, but failure could see stock revisit sub-$0.5 levels. Read the full article on Seeking AlphaMise à jour du récit • Mar 10
IVVD: Fast Track Phase 3 COVID Prevention Program Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to reflect updated assumptions around revenue growth of 71.06%, a profit margin of 5.97% and a future P/E of 266.11x. These assumptions result in a revised fair value estimate of $10.00 per share.Mise à jour du récit • Feb 23
IVVD: Phase 3 Fast Track COVID Prevention Trials Will Support Future Upside
Analysts have kept their fair value estimate for Invivyd steady at $10.00. A slightly lower discount rate and modestly softer profit margin outlook, paired with a marginally higher future P/E assumption, reflect a more finely balanced view of the company’s risk and earnings potential.Mise à jour du récit • Feb 09
IVVD: Phase 3 Fast Track COVID Prevention Program Will Drive Future Upside
Analysts have trimmed their price target on Invivyd to US$10, citing updated assumptions that include a slightly higher discount rate, modestly reduced profit margin expectations, and a higher future P/E multiple. What's in the News FDA granted Fast Track designation for VYD2311, Invivyd's vaccine alternative monoclonal antibody candidate for prevention of COVID in individuals with underlying risk factors for severe disease, aligning the program with an expedited U.S. regulatory process (Key Developments).Article d’analyse • Jan 29
Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk
The Invivyd, Inc. ( NASDAQ:IVVD ) share price has softened a substantial 26% over the previous 30 days, handing back...Mise à jour du récit • Jan 24
IVVD: REVOLUTION Program Will Define Future Upside As COVID Prevention Alternative
Analysts have lifted their price target on Invivyd to US$10 from US$5, citing the launch of the REVOLUTION clinical program for VYD2311 as a key driver behind their updated view. Analyst Commentary Analysts are reacting to the REVOLUTION program for VYD2311 as a key event for Invivyd, and the updated US$10 price target reflects how they are recalibrating risk and potential upside around this new clinical path.Mise à jour du récit • Jan 08
IVVD: REVOLUTION Program And Fast Track Status Will Support Future Upside Potential
Narrative Update on Invivyd Analysts have lifted their price target on Invivyd to US$10 from US$5, pointing to the launch of the REVOLUTION clinical program for VYD2311 as a key factor that they believe strengthens the company’s regulatory and commercial position. Analyst Commentary Recent Street research around Invivyd has focused squarely on the launch of the REVOLUTION clinical program for VYD2311, with bullish analysts recalibrating their expectations for the company’s potential market position and execution risk.Mise à jour du récit • Dec 18
IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside
Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION clinical program for VYD2311 as a meaningful inflection point that enhances the company’s regulatory and commercial outlook. Analyst Commentary Following the launch of the REVOLUTION clinical program for VYD2311, equity research has focused on how the new data and development path could reshape Invivyd's long term growth and valuation profile.Mise à jour du récit • Dec 04
IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside
Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION program for VYD2311 as a key inflection point that improves the company's regulatory and commercial outlook. Analyst Commentary Analysts interpreting the updated price target see the REVOLUTION program as a pivotal moment for Invivyd, shifting expectations for both execution and long term growth potential.Article d’analyse • Nov 29
Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking
Despite an already strong run, Invivyd, Inc. ( NASDAQ:IVVD ) shares have been powering on, with a gain of 27% in the...Mise à jour du récit • Nov 20
IVVD: REVOLUTION Program Initiation Will Drive Regulatory Momentum and Commercial Outlook
Analysts have raised their price target for Invivyd from $5 to $10, citing the launch of the REVOLUTION clinical program as a pivotal development. This new program is expected to enhance the company's regulatory and commercial outlook.Mise à jour du récit • Nov 05
IVVD: FDA Clearance and REVOLUTION Program Launch Signal Strong Upside Ahead
Narrative Update: Invivyd Analyst Price Target Increased Invivyd's analyst price target has been raised from $5.67 to $7.33 per share. Analysts cite strengthened commercial and regulatory prospects following the launch of the REVOLUTION clinical program.Mise à jour du récit • Oct 22
Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update
Narrative Update on Invivyd: Analyst Price Target Revision Analysts have maintained Invivyd's price target at $5.67, citing consistent profit margin expectations along with only minor adjustments to the discount rate and future earnings estimates. What's in the News The FDA has cleared Invivyd's Investigational New Drug application, advancing the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Product-Related Announcements).Article d’analyse • Oct 14
Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Invivyd, Inc. ( NASDAQ:IVVD ) shares have continued their recent momentum with a 31% gain in the last month alone. The...Mise à jour du récit • Oct 08
Internal Sales And Antibody Pipeline Will Broaden Patient Reach
Narrative Update on Invivyd Price Target Analysts have raised Invivyd’s price target from $3.00 to $5.67, citing updated forecasts and changes in market expectations. What's in the News The U.S. FDA cleared Invivyd’s Investigational New Drug application, enabling advancement of the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Key Developments).Article d’analyse • Aug 22
Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge
Invivyd, Inc. ( NASDAQ:IVVD ) shareholders that were waiting for something to happen have been dealt a blow with a 31...Mise à jour du récit • Aug 16
Internal Sales And Antibody Pipeline Will Broaden Patient Reach
Invivyd’s fair value estimate has been sharply reduced, driven by lowered revenue growth projections and a decline in expected net profit margins, resulting in a consensus analyst price target drop from $4.93 to $2.93. What's in the News Invivyd’s monoclonal antibody pemivibart (PEMGARDA) has shown strong protection (84% relative risk reduction) against symptomatic COVID-19 in immunocompromised and at-risk populations in the placebo-controlled CANOPY Phase 3 trial, supporting its Emergency Use Authorization (EUA) for pre-exposure prophylaxis.
Nouveau récit • Apr 23
Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025
The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs.Seeking Alpha • Feb 04
I See The Bull Case For Invivyd, But I'm Not Married To It
Summary Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% revenue increase for PEMGARDA and a 55% drop in operating expenses highlights Invivyd's potential for profitability. VYD2311 shows significant promise with high neutralization potency and durability, but faces regulatory and competitive challenges before market approval. Invivyd is a speculative bet with potential for high rewards; suitable for risk-tolerant investors, but stability seekers should avoid. Read the full article on Seeking AlphaArticle d’analyse • Feb 01
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Article d’analyse • Jul 16
Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Article d’analyse • Mar 29
Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, Invivyd ( NASDAQ:IVVD...Article d’analyse • Oct 24
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Article d’analyse • Jul 04
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Article d’analyse • Mar 19
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Rendement pour les actionnaires
| IVVD | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -25.9% | -4.9% | -1.0% |
| 1Y | 42.6% | 28.1% | 23.3% |
Rendement vs Industrie: IVVD a dépassé le secteur US Biotechs qui a rapporté 28.1 % au cours de l'année écoulée.
Rendement vs marché: IVVD a dépassé le marché US qui a rapporté 23.3 % au cours de l'année écoulée.
Volatilité des prix
| IVVD volatility | |
|---|---|
| IVVD Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de IVVD a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de IVVD ( 15% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2020 | 122 | Bill Duke | www.invivyd.com |
Invivyd, Inc. et ses filiales se consacrent à la recherche, au développement, à la commercialisation et à la vente de thérapies à base d'anticorps pour la prévention et le traitement des maladies infectieuses virales aux États-Unis. La société propose Pemivibart, un anticorps monoclonal expérimental à demi-vie prolongée pour la prophylaxie pré-exposition au COVID-19 chez les adultes et les adolescents par injection sous la marque PEMGARDA. Elle développe également le VYD2311, un anticorps monoclonal, qui est en phase III d'essai clinique pour la prévention et le traitement du virus SARS-CoV-2, et le VBY329, un anticorps monoclonal, qui est en phase d'essai préclinique pour la prévention et le traitement du virus respiratoire syncytial et de la rougeole chez les nouveau-nés, les nourrissons et les enfants.
Invivyd, Inc. Résumé des fondamentaux
| IVVD statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$294.12m |
| Bénéfices(TTM) | -US$77.60m |
| Recettes(TTM) | US$55.87m |
5.5x
Ratio P/S-4.0x
Ratio P/ELe site IVVD est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| IVVD compte de résultat (TTM) | |
|---|---|
| Recettes | US$55.87m |
| Coût des recettes | US$3.95m |
| Marge brute | US$51.92m |
| Autres dépenses | US$129.52m |
| Les revenus | -US$77.60m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.27 |
| Marge brute | 92.94% |
| Marge bénéficiaire nette | -138.90% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de IVVD?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 02:09 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Invivyd, Inc. est couverte par 5 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Patrick Trucchio | H.C. Wainwright & Co. |